NeoHack Word Wide Market Currently $115 billion
Doctor Brown's Blog
March 21, 2026 Breaking the Cycle of Pain: The Multi-Billion Dollar Markets Addressed
NeoHack Life Sciences has secured two pivotal patents, No. 12,370,156 and No. 12,303,476, which cover novel "Compositions and Methods of Achieving Pain Relief." These patents utilize a synergistic blend of natural alkaloids (spilanthol and pellitorine) and pro-vitamin B5 to target a wide array of inflammatory and neuropathic conditions.
By addressing complex disorders ranging from chronic joint pain to Alzheimer’s disease, these patents position the company within some of the world’s most significant therapeutic markets. Below is an analysis of the diseases addressed by these claims and the worldwide spending (market size) associated with treating them, currently over $115 billion.
1. Pain Management (Joint & Neuropathic Pain)
The primary claim of the patents focuses on alleviating pain through topical and oral delivery. This includes relief from joint inflammation (arthritis) and neuropathic pain, offering a natural alternative to traditional NSAIDs and opioids.
- Addressed Condition: Chronic musculoskeletal pain, arthritis, and nerve damage.
- Global Market Size: ~$76.0 billion (2024)
- The global pain management drug market is valued at approximately $76.02 billion in 2024 and is projected to reach over $123 billion by 2035. The demand is driven heavily by an aging population and the opioid crisis, which has created an urgent need for non-addictive pain management solutions like those proposed in NeoHack's patents.
2. Viral Skin Diseases (Herpes & Molluscum)
The patents extend to the treatment of viral skin infections, specifically targeting the pain and lesions associated with these conditions. The "tingling" and "burning" sensations common in these outbreaks are main targets for the spilanthol-based formulations.
- Addressed Conditions: Herpes Labialis (Cold Sores), Shingles (Herpes Zoster), and Molluscum Contagiosum.
- Global Market Size: ~$8.6 billion (Combined Segments)
- Herpes Simplex Treatment: The market for treating herpes infections (specifically HSV-1 and HSV-2) is valued at approximately $2.5 billion.
- Cold Sore (Herpes Labialis) Specific: The niche market for topical cold sore treatments alone is valued at ~$1.0 billion.
- Molluscum Contagiosum: Treatment spending for this viral skin condition reached ~$2.78 billion in 2024.
- Shingles (Herpes Zoster): While the vaccine market is larger, the therapeutic market for treating active Shingles outbreaks and post-herpetic neuralgia is estimated at ~$2.4 billion.
3. Inflammatory Skin Diseases
Beyond viral causes, the patents cover general inflammatory skin diseases. The pro-vitamin B5 component is well-regarded for its ability to repair the skin barrier and soothe irritation in conditions like eczema and dermatitis.
- Addressed Conditions: Atopic dermatitis (Eczema), Contact Dermatitis, and general skin inflammation.
- Global Market Size: ~$24.0 billion
- The broader dermatological drugs market is valued at ~$23.9 billion in 2024. Specifically, the Atopic Dermatitis market accounts for ~$6.6 billion of these totals, representing a massive sector of patients seeking non-steroidal topical relief.
4. Alzheimer’s Disease & Neurodegeneration
One of the most advanced claims in the patents involves the potential for these compositions to address neurodegenerative disorders. Spilanthol has been investigated for its ability to cross the blood-brain barrier and potentially influence neurological pathways.
- Addressed Condition: Alzheimer’s Disease and associated neurodegeneration.
- Global Market Size: ~$5.0 billion
- The global Alzheimer’s therapeutics market is currently valued at approximately $4.98 billion (2024). However, this figure is expected to triple to over $15 billion by 2030 as disease-modifying treatments enter the market.
- Note: The total economic burden of Alzheimer's (caregiving, lost wages, etc.) is estimated in the trillions, highlighting the high value of any treatment that can manage symptoms or slow progression.
5. Sjogren’s Syndrome
The patents specifically list Sjogren’s Syndrome, an autoimmune disorder that attacks the glands that produce tears and saliva. The formulations aim to manage the chronic pain and dryness associated with this systemic condition.
- Addressed Condition: Sjogren’s Syndrome (specifically symptom management of dryness and pain).
- Global Market Size: ~$271 million
- Spending on therapeutics specifically for Sjogren's Syndrome is estimated at $271 million in 2024. While a smaller niche than Alzheimer's, it is a market with very few effective approved treatments, mar820king it as an area of high unmet need.
6.Radiation Dermatitis
Global Market Size: $820 Million Projected
- Spending on therapeutics specifically for RD is projected at $820 million by 2032. It affects approximately 95% of radiotherapy patients. Beyond the $4,500 to $50,000 cost of radiation treatment, patients face significant out-of-pocket expenses for skin-related self-care, highlighting a high unmet need for standardized, non-steroidal treatments.
Stem Cells are nature's healing tools, mobilizing endogenous stem cells now possible
with NeoHack’s recent patent
January 14, 2026
As of 2026, regenerative medicine for Alzheimer’s disease (AD) has shifted toward stimulating the brain’s innate repair mechanisms. Research into bioactive compounds like β-caryophyllene, dexpanthenol, and spilanthol highlights their potential to activate endogenous neural stem cells (NSCs), offering a multi-faceted approach to restoring cognitive function and mitigating neurodegeneration. See our 2025 patents at https://neohacksciences.com/newest-patents .
Spilanthol: The Emerging Stem Cell Secretagogue* (see definition below)
Spilanthol, an alkylamide derived from Acmella oleracea (the "toothache plant"), is increasingly recognized for its ability to penetrate the blood-brain barrier and modulate neural signaling.
- Stem Cell Recruitment: Recent findings suggest spilanthol acts as a chemical "secretagogue," triggering the release of endogenous growth factors that recruit NSCs to damaged neural tissues.
- Anti-Inflammatory Synergy: Like aromatic-turmerone, spilanthol may inhibit p38 MAP kinase activity, which prevents the premature differentiation of NSCs into glia (scar tissue) and instead favors their development into functional neurons.
- Cognitive Enhancement: By dampening microglial overactivation, spilanthol protects the newly generated endogenous cells from the toxic inflammatory milieu characteristic of the AD brain.
Caryophyllene: A Cannabinoid-Like Neuroprotector
Beta-caryophyllene (BCP) is a dietary sesquiterpene found in black pepper, cloves, and rosemary. It acts as a selective agonist for the cannabinoid receptor type 2 (CB2), which is prominently expressed in the central nervous system during neuroinflammatory states.
- Endogenous Stem Cell Activation: Studies in late 2025 demonstrate that BCP facilitates the proliferation of endogenous NSCs in the hippocampus, a primary site of AD-related atrophy.
- Mechanisms of Action: BCP enhances the expression of brain-derived neurotrophic factor (BDNF), a critical signal for stem cell differentiation and synaptic plasticity.
- AD Pathology Mitigation: Preclinical models show BCP reduces amyloid-beta (Aβ) plaque accumulation and inhibits neuroinflammatory pathways (JAK2/STAT3), which typically suppress the regenerative capacity of dormant stem cells.
Dexpanthenol: Cholinergic Support and Neurodegeneration
Dexpanthenol, a precursor to Vitamin B5 (pantothenic acid), is traditionally known for its wound-healing properties but has emerged as a potent neuroprotective agent in AD research.
- Cholinergic Restoration: It is essential for the synthesis of acetylcholine, the neurotransmitter most severely depleted in AD.
- Neurogenesis Promotion: By reducing oxidative stress and neuroinflammation, dexpanthenol creates a permissive environment for endogenous NSCs to thrive.
- Hippocampal Preservation: Research indicates that dexpanthenol prevents neuronal loss in the cornu ammonis (CA1 and CA3) regions, effectively reversing memory deficits in sporadic-AD models by supporting the survival of newly formed neurons.
Clinical Outlook in 2026
The integration of these ingredients represents a paradigm shift from "cell replacement" (transplantation) to "cell activation" (regeneration). In late 2025, phase 1 and 2 trials began exploring autologous stem cell approaches that utilize similar molecular pathways to stimulate dormant ventricular stem cells. While not yet a standalone "cure," the combination of BCP, dexpanthenol, and spilanthol offers a promising strategy to slow, and potentially reverse, the cognitive decline associated with Alzheimer's disease.
*A secretagogue is an agent that promotes the secretion of hormones, neurohormones, chemical neurotransmitters, enzymes, or other compounds synthesized and secreted by cells.
NeoHack Life Sciences senior managers may be reached via the emails below for information regarding licensing rights for 20 of its patented claims:
CEO, Ron Butler email: rb@neohacksciences.com
CSO, Dr. Dale Brown email: db@neohacksciences.comAnyone will tell you that the science of "pain management" in the last two decades has been fraught with miscalculations, missteps and outright abuses. It has largely produced only what it says: management. Believing that management was not enough, NeoHack set out to learn new sources of relief and better systemic applications from the best teacher of all -- nature. Read on to learn what we found.